Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Most loved Road Food: Which One Prevails upon You? - 2L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- 3Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- 4Historical mysteries solved by science in 2025
- 5Building an Individual Brand: Illustrations from Powerhouses
- The Job of a Land Legal counselor in Property Exchanges
- Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- Cyprus urges hotels to open up, pours funding into tourism
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- Young Muslims in Germany feel left out of Mideast debate, experts say
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
